PATENT CLAIM ANALYSIS

Application Number: 16106345
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "342000"]

Abstract:
A pharmaceutical combination comprising: (a) an alpha-isoform specific phosphatidylinositol-3-kinase inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) an mTOR inhibitor and (c) exemestane or any pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the preparation of a medicament for the treatment or prevention of a proliferative disease; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.

Claim (Index 4):
A pharmaceutical combination according to  claim 2 , wherein the proliferative disease is a hormone-receptor positive breast cancer.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.85294
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15646494', '13799076', '14240499', '14429367', '15719636']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7689368340054743
- 35 USC 102 Novelty (BERT): 0.5399810732911476
- Combined Prediction Score: 0.7460412579340417
- Mean Citation Score: 307.719622
- Max Citation Score: 351.56668
- Similarity Product: 198.87238404190305

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test